|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-4-15
|
|
pubmed:abstractText |
Systemic treatments of advanced hepatocellular carcinoma (AHCC) have offered marginal clinical benefits. Recently, Italian investigators reported that etoposide and epirubicin combination (EE) chemotherapy was highly active against AHCC, with a response rate of 39% and a median overall survival (OS) of 10 months. We report our efficacy and safety results of EE in clinical practice.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1440-1746
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
811-6
|
|
pubmed:meshHeading |
pubmed-meshheading:17995941-Adolescent,
pubmed-meshheading:17995941-Adult,
pubmed-meshheading:17995941-Aged,
pubmed-meshheading:17995941-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17995941-Carcinoma, Hepatocellular,
pubmed-meshheading:17995941-Epirubicin,
pubmed-meshheading:17995941-Etoposide,
pubmed-meshheading:17995941-Female,
pubmed-meshheading:17995941-Humans,
pubmed-meshheading:17995941-Liver Neoplasms,
pubmed-meshheading:17995941-Male,
pubmed-meshheading:17995941-Middle Aged,
pubmed-meshheading:17995941-Neoplasm Staging,
pubmed-meshheading:17995941-Retrospective Studies
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis.
|
|
pubmed:affiliation |
Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
